Regeneron Pharmaceuticals, Inc. (0R2M.L)
USD 607.93
(4.12%)
USD 607.93
(4.12%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 13.11 Billion USD | 7.76% |
| 2022 | 12.17 Billion USD | -24.26% |
| 2021 | 16.07 Billion USD | 89.14% |
| 2020 | 8.49 Billion USD | 8.06% |
| 2019 | 7.86 Billion USD | 17.18% |
| 2018 | 6.71 Billion USD | 14.28% |
| 2017 | 5.87 Billion USD | 20.82% |
| 2016 | 4.86 Billion USD | 18.44% |
| 2015 | 4.1 Billion USD | 45.55% |
| 2014 | 2.81 Billion USD | 33.96% |
| 2013 | 2.1 Billion USD | 52.69% |
| 2012 | 1.37 Billion USD | 209.2% |
| 2011 | 445.82 Million USD | -2.89% |
| 2010 | 459.07 Million USD | 21.04% |
| 2009 | 379.26 Million USD | 59.05% |
| 2008 | 238.45 Million USD | 90.73% |
| 2007 | 125.02 Million USD | 97.05% |
| 2006 | 63.44 Million USD | -4.15% |
| 2005 | 66.19 Million USD | -61.96% |
| 2004 | 174.01 Million USD | 202.65% |
| 2003 | 57.49 Million USD | 161.49% |
| 2002 | 21.98 Million USD | 0.07% |
| 2001 | 21.97 Million USD | -62.93% |
| 2000 | 59.27 Million USD | 71.81% |
| 1999 | 34.5 Million USD | -9.69% |
| 1998 | 38.2 Million USD | 15.41% |
| 1997 | 33.1 Million USD | 37.34% |
| 1996 | 24.1 Million USD | -12.04% |
| 1995 | 27.4 Million USD | 18.1% |
| 1994 | 23.2 Million USD | 118.87% |
| 1993 | 10.6 Million USD | -7.83% |
| 1992 | 11.5 Million USD | 57.53% |
| 1991 | 7.3 Million USD | 46.0% |
| 1990 | 5 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 3.54 Billion USD | 12.79% |
| 2024 Q1 | 3.14 Billion USD | -8.42% |
| 2024 Q3 | 3.72 Billion USD | 4.89% |
| 2023 Q3 | 3.36 Billion USD | 6.48% |
| 2023 FY | 13.11 Billion USD | 7.76% |
| 2023 Q2 | 3.15 Billion USD | -0.13% |
| 2023 Q1 | 3.16 Billion USD | -7.39% |
| 2023 Q4 | 3.43 Billion USD | 2.13% |
| 2022 Q4 | 3.41 Billion USD | 16.29% |
| 2022 Q2 | 2.85 Billion USD | -3.64% |
| 2022 Q1 | 2.96 Billion USD | -40.12% |
| 2022 Q3 | 2.93 Billion USD | 2.76% |
| 2022 FY | 12.17 Billion USD | -24.26% |
| 2021 Q1 | 2.52 Billion USD | 4.37% |
| 2021 Q3 | 3.45 Billion USD | -32.81% |
| 2021 Q4 | 4.95 Billion USD | 43.41% |
| 2021 FY | 16.07 Billion USD | 89.14% |
| 2021 Q2 | 5.13 Billion USD | 103.21% |
| 2020 Q3 | 2.29 Billion USD | 17.52% |
| 2020 FY | 8.49 Billion USD | 8.06% |
| 2020 Q2 | 1.95 Billion USD | 6.77% |
| 2020 Q1 | 1.82 Billion USD | -15.73% |
| 2020 Q4 | 2.42 Billion USD | 5.62% |
| 2019 FY | 7.86 Billion USD | 17.18% |
| 2019 Q4 | 2.16 Billion USD | 5.91% |
| 2019 Q3 | 2.04 Billion USD | 5.93% |
| 2019 Q2 | 1.93 Billion USD | 12.96% |
| 2019 Q1 | 1.71 Billion USD | -11.2% |
| 2018 Q4 | 1.92 Billion USD | 15.89% |
| 2018 FY | 6.71 Billion USD | 14.28% |
| 2018 Q3 | 1.66 Billion USD | 3.45% |
| 2018 Q2 | 1.6 Billion USD | 6.39% |
| 2018 Q1 | 1.51 Billion USD | -4.48% |
| 2017 Q1 | 1.31 Billion USD | 7.51% |
| 2017 FY | 5.87 Billion USD | 20.82% |
| 2017 Q3 | 1.5 Billion USD | 2.08% |
| 2017 Q4 | 1.58 Billion USD | 5.45% |
| 2017 Q2 | 1.47 Billion USD | 11.46% |
| 2016 Q4 | 1.22 Billion USD | 0.55% |
| 2016 Q1 | 1.2 Billion USD | 9.36% |
| 2016 Q2 | 1.21 Billion USD | 0.98% |
| 2016 FY | 4.86 Billion USD | 18.44% |
| 2016 Q3 | 1.22 Billion USD | 0.62% |
| 2015 Q3 | 1.13 Billion USD | 13.9% |
| 2015 FY | 4.1 Billion USD | 45.55% |
| 2015 Q1 | 869.61 Million USD | 8.39% |
| 2015 Q2 | 998.61 Million USD | 14.83% |
| 2015 Q4 | 1.09 Billion USD | -3.46% |
| 2014 Q4 | 802.32 Million USD | 10.55% |
| 2014 FY | 2.81 Billion USD | 33.96% |
| 2014 Q1 | 625.74 Million USD | 2.51% |
| 2014 Q2 | 665.7 Million USD | 6.39% |
| 2014 Q3 | 725.78 Million USD | 9.03% |
| 2013 Q4 | 610.41 Million USD | 2.24% |
| 2013 FY | 2.1 Billion USD | 52.69% |
| 2013 Q3 | 597.02 Million USD | 30.46% |
| 2013 Q2 | 457.64 Million USD | 4.09% |
| 2013 Q1 | 439.66 Million USD | 6.04% |
| 2012 FY | 1.37 Billion USD | 209.2% |
| 2012 Q4 | 414.6 Million USD | -3.06% |
| 2012 Q1 | 231.78 Million USD | 88.48% |
| 2012 Q2 | 304.39 Million USD | 31.33% |
| 2012 Q3 | 427.68 Million USD | 40.5% |
| 2011 Q1 | 112.2 Million USD | -16.06% |
| 2011 Q4 | 122.97 Million USD | 19.59% |
| 2011 Q2 | 107.81 Million USD | -3.92% |
| 2011 FY | 445.82 Million USD | -2.89% |
| 2011 Q3 | 102.83 Million USD | -4.62% |
| 2010 Q2 | 115.88 Million USD | 11.93% |
| 2010 FY | 459.07 Million USD | 21.04% |
| 2010 Q3 | 105.97 Million USD | -8.55% |
| 2010 Q4 | 133.67 Million USD | 26.13% |
| 2010 Q1 | 103.53 Million USD | 6.96% |
| 2009 Q1 | 74.98 Million USD | 34.29% |
| 2009 Q2 | 90.03 Million USD | 20.07% |
| 2009 Q3 | 117.45 Million USD | 30.46% |
| 2009 Q4 | 96.8 Million USD | -17.59% |
| 2009 FY | 379.26 Million USD | 59.05% |
| 2008 FY | 238.45 Million USD | 90.73% |
| 2008 Q4 | 55.83 Million USD | -14.86% |
| 2008 Q3 | 65.58 Million USD | 8.13% |
| 2008 Q2 | 60.65 Million USD | 7.57% |
| 2008 Q1 | 56.38 Million USD | -12.9% |
| 2007 Q3 | 22.31 Million USD | 0.52% |
| 2007 Q4 | 64.73 Million USD | 190.13% |
| 2007 FY | 125.02 Million USD | 97.05% |
| 2007 Q2 | 22.19 Million USD | 40.58% |
| 2007 Q1 | 15.78 Million USD | 52.6% |
| 2006 Q4 | 10.34 Million USD | -33.78% |
| 2006 FY | 63.44 Million USD | -4.15% |
| 2006 Q3 | 15.62 Million USD | -18.87% |
| 2006 Q2 | 19.25 Million USD | 5.7% |
| 2006 Q1 | 18.21 Million USD | 4.56% |
| 2005 Q3 | 16.19 Million USD | -1.05% |
| 2005 FY | 66.19 Million USD | -61.96% |
| 2005 Q2 | 16.36 Million USD | 0.97% |
| 2005 Q1 | 16.2 Million USD | -65.58% |
| 2005 Q4 | 17.42 Million USD | 7.6% |
| 2004 Q1 | 61.99 Million USD | 191.42% |
| 2004 FY | 174.01 Million USD | 202.65% |
| 2004 Q4 | 47.09 Million USD | 28.95% |
| 2004 Q3 | 36.51 Million USD | 28.51% |
| 2004 Q2 | 28.41 Million USD | -54.16% |
| 2003 Q2 | 10.53 Million USD | 3.91% |
| 2003 Q4 | 21.27 Million USD | 22.31% |
| 2003 FY | 57.49 Million USD | 161.49% |
| 2003 Q3 | 17.39 Million USD | 65.13% |
| 2003 Q1 | 10.13 Million USD | 106.35% |
| 2002 Q2 | 5.56 Million USD | 12.71% |
| 2002 Q1 | 4.94 Million USD | 12.27% |
| 2002 Q3 | 6.56 Million USD | 17.9% |
| 2002 Q4 | 4.91 Million USD | -25.19% |
| 2002 FY | 21.98 Million USD | 0.07% |
| 2001 Q3 | 5.48 Million USD | -5.17% |
| 2001 FY | 21.97 Million USD | -62.93% |
| 2001 Q1 | 9.08 Million USD | -53.21% |
| 2001 Q2 | 5.77 Million USD | -36.39% |
| 2001 Q4 | 4.4 Million USD | -19.69% |
| 2000 Q3 | 14.9 Million USD | 3.11% |
| 2000 Q2 | 14.45 Million USD | 37.7% |
| 2000 FY | 59.27 Million USD | 71.81% |
| 2000 Q1 | 10.49 Million USD | -11.78% |
| 2000 Q4 | 19.41 Million USD | 30.26% |
| 1999 Q1 | 5.5 Million USD | -25.68% |
| 1999 FY | 34.5 Million USD | -9.69% |
| 1999 Q4 | 11.9 Million USD | 5.31% |
| 1999 Q3 | 11.3 Million USD | 91.53% |
| 1999 Q2 | 5.9 Million USD | 7.27% |
| 1998 FY | 38.2 Million USD | 15.41% |
| 1998 Q3 | 10.8 Million USD | -20.0% |
| 1998 Q4 | 7.4 Million USD | -31.48% |
| 1998 Q1 | 6.5 Million USD | -42.98% |
| 1998 Q2 | 13.5 Million USD | 107.69% |
| 1997 Q3 | 8.9 Million USD | 34.85% |
| 1997 Q1 | 6.2 Million USD | -4.62% |
| 1997 FY | 33.1 Million USD | 37.34% |
| 1997 Q4 | 11.4 Million USD | 28.09% |
| 1997 Q2 | 6.6 Million USD | 6.45% |
| 1996 Q2 | 6.2 Million USD | 19.23% |
| 1996 Q4 | 6.5 Million USD | 4.84% |
| 1996 Q1 | 5.2 Million USD | -10.34% |
| 1996 FY | 24.1 Million USD | -12.04% |
| 1996 Q3 | 6.2 Million USD | 0.0% |
| 1995 FY | 27.4 Million USD | 18.1% |
| 1995 Q4 | 5.8 Million USD | -6.45% |
| 1995 Q3 | 6.2 Million USD | -18.42% |
| 1995 Q2 | 7.6 Million USD | 10.14% |
| 1995 Q1 | 6.9 Million USD | -10.39% |
| 1994 Q2 | 3.6 Million USD | 20.0% |
| 1994 Q4 | 7.7 Million USD | -13.48% |
| 1994 FY | 23.2 Million USD | 118.87% |
| 1994 Q3 | 8.9 Million USD | 147.22% |
| 1994 Q1 | 3 Million USD | 3.45% |
| 1993 Q2 | 1.3 Million USD | -38.1% |
| 1993 Q4 | 2.9 Million USD | -19.44% |
| 1993 Q3 | 3.6 Million USD | 176.92% |
| 1993 FY | 10.6 Million USD | -7.83% |
| 1993 Q1 | 2.1 Million USD | -8.7% |
| 1992 Q3 | 2.4 Million USD | -25.0% |
| 1992 Q1 | 3.5 Million USD | 75.0% |
| 1992 FY | 11.5 Million USD | 57.53% |
| 1992 Q4 | 2.3 Million USD | -4.17% |
| 1992 Q2 | 3.2 Million USD | -8.57% |
| 1991 Q1 | 2 Million USD | 53.85% |
| 1991 Q3 | 1.9 Million USD | 11.76% |
| 1991 Q4 | 2 Million USD | 5.26% |
| 1991 FY | 7.3 Million USD | 46.0% |
| 1991 Q2 | 1.7 Million USD | -15.0% |
| 1990 Q1 | 1.2 Million USD | 0.0% |
| 1990 FY | 5 Million USD | 0.0% |
| 1990 Q4 | 1.3 Million USD | 0.0% |
| 1990 Q3 | 1.3 Million USD | 8.33% |
| 1990 Q2 | 1.2 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | -16690.446% |
| Dynavax Technologies Corporation | 232.28 Million USD | -5547.053% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -62458.184% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 91.116% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -2059.135% |
| Perrigo Company plc | 4.65 Billion USD | -181.751% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -152905.949% |
| Illumina, Inc. | 4.5 Billion USD | -191.234% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 69.393% |
| Nektar Therapeutics | 90.12 Million USD | -14454.937% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -1103112.784% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 12.459% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -10224.927% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | -442.206% |
| Waters Corporation | 2.95 Billion USD | -343.686% |
| Biogen Inc. | 9.83 Billion USD | -33.365% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -7343.143% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 202.08 Million USD | -6390.932% |
| bluebird bio, Inc. | 29.49 Million USD | -44369.607% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -41876.383% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -11175.465% |
| FibroGen, Inc. | 147.75 Million USD | -8777.849% |
| Agilent Technologies, Inc. | 6.83 Billion USD | -91.968% |
| Homology Medicines, Inc. | -6.65 Million USD | 197321.47% |
| Geron Corporation | 237 Thousand USD | -5534583.544% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -617.457% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -3184.588% |
| Myriad Genetics, Inc. | 678.4 Million USD | -1833.55% |
| OPKO Health, Inc. | 863.49 Million USD | -1419.082% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -36060.441% |
| Zoetis Inc. | 8.54 Billion USD | -53.525% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -374677.143% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | -246.255% |
| Exelixis, Inc. | 1.83 Billion USD | -616.705% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | -32.91% |
| uniQure N.V. | 15.84 Million USD | -82694.925% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -4747.45% |
| Verastem, Inc. | - USD | -Infinity% |
| Imunon, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -1565.365% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -955.0% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | -595.098% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -2619.295% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -1481.809% |
| TG Therapeutics, Inc. | 233.66 Million USD | -5513.75% |
| Blueprint Medicines Corporation | 249.38 Million USD | -5159.925% |
| Insmed Incorporated | 305.2 Million USD | -4197.79% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -48802.807% |
| Incyte Corporation | 3.69 Billion USD | -254.936% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -1150.091% |